Chronic Hepatitis B Market - A Global and Regional Analysis

2.1 North America
      2.1.1 Key Findings
      2.1.2 Market Dynamics
      2.1.3 Market Sizing and Forecast
               2.1.3.1 North America Chronic Hepatitis B Market (by Country)
               2.1.3.2 U.S.
               2.1.3.3 Canada
2.2 Europe
      2.2.1 Key Findings
      2.2.2 Market Dynamics
      2.2.3 Market Sizing and Forecast
               2.2.3.1 Europe Chronic Hepatitis B Market (by Country)
                           2.2.3.1.1 U.K.
                           2.2.3.1.2 Germany
                           2.2.3.1.3 France
                           2.2.3.1.4 Italy
                           2.2.3.1.5 Spain
                           2.2.3.1.6 Rest-of-Europe
2.3 Asia-Pacific
      2.3.1 Key Findings
      2.3.2 Market Dynamics
      2.3.3 Market Sizing and Forecast
               2.3.3.1 Asia-Pacific Chronic Hepatitis B Market (by Country)
                           2.3.3.1.1 Japan
                           2.3.3.1.2 China
                           2.3.3.1.3 India
                           2.3.3.1.4 Australia
                           2.3.3.1.5 South Korea
                           2.3.3.1.6 Rest-of-Asia-Pacific
2.4 Rest-of-the-World
      2.4.1 Key Findings
      2.4.2 Market Dynamics
      2.4.3 Market Size and Forecast

3.1 Competitive Benchmarking
3.2 Competitive Landscape
       3.2.1 Key Strategies and Developments by Company
                3.2.1.1 Funding Activities
                3.2.1.2 Mergers and Acquisitions
                3.2.1.3 Regulatory Approvals
                3.2.1.4 Partnerships, Collaborations and Business Expansions
       3.2.2 Key Developments Analysis
3.3 Company Profiles
       3.3.1 Gilead Sciences, Inc.
                3.3.1.1 Company Overview
                3.3.1.2 Product Portfolio
                3.3.1.3 Target Customers/End Users
                3.3.1.4 Analyst View
       3.3.2 GlaxoSmithKline
                3.3.2.1 Company Overview
                3.3.2.2 Product Portfolio
                3.3.2.3 Target Customers/End Users
                3.3.2.4 Analyst View               
       3.3.3 Ionis Pharmaceuticals, Inc.
                3.3.3.1 Company Overview
                3.3.3.2 Product Portfolio
                3.3.3.3 Target Customers/End Users
                3.3.3.4 Analyst View
       3.3.4 Gyre Therapeutics
                3.3.4.1 Company Overview
                3.3.4.2 Product Portfolio
                3.3.4.3 Target Customers/End Users
                3.3.4.4 Analyst View               
       3.3.5 Ascletis Pharmaceuticals
                3.3.5.1 Company Overview
                3.3.5.2 Product Portfolio
                3.3.5.3 Target Customers/End Users
                3.3.5.4 Analyst View
       3.3.6 Vir Biotechnology, Inc.
                3.3.6.1 Company Overview
                3.3.6.2 Product Portfolio
                3.3.6.3 Target Customers/End Users
                3.3.6.4 Analyst View
       3.3.7 Brii Biosciences Limited
                3.3.7.1 Company Overview
                3.3.7.2 Product Portfolio
                3.3.7.3 Target Customers/End Users
                3.3.7.4 Analyst View
       3.3.8 Arrowhead Pharmaceuticals Inc.
                3.3.8.1 Company Overview
                3.3.8.2 Product Portfolio
                3.3.8.3 Target Customers/End Users
                3.3.8.4 Analyst View
       3.3.9 Johnson & Johnson
                3.3.9.1 Company Overview
                3.3.9.2 Product Portfolio
                3.3.9.3 Target Customers/End Users
                3.3.9.4 Analyst View
       3.3.10 Sino Biopharmaceutical Limited
                3.3.10.1 Company Overview
                3.3.10.2 Product Portfolio
                3.3.10.3 Target Customers/End Users
                3.3.10.4 Analyst View               
       3.3.11 Arbutus Biopharma Corporation
                3.3.11.1 Company Overview
                3.3.11.2 Product Portfolio
                3.3.11.3 Target Customers/End Users
                3.3.11.4 Analyst View
       3.3.12 Virion Therapeutics, LLC
                3.3.12.1 Company Overview
                3.3.12.2 Product Portfolio
                3.3.12.3 Target Customers/End Users
                3.3.12.4 Analyst View
       3.3.13 AusperBio Therapeutics, Inc.
                3.3.13.1 Company Overview
                3.3.13.2 Product Portfolio
                3.3.13.3 Target Customers/End Users
                3.3.13.4 Analyst View
       3.3.14 Precision Bioscience
                3.3.14.1 Company Overview
                3.3.14.2 Product Portfolio
                3.3.14.3 Target Customers/End Users
                3.3.14.4 Analyst View

Table: Global Chronic Hepatitis B Market, Regulatory Scenario
Table: Global Chronic Hepatitis B Market Dynamics, Impact Analysis

Figure: Global Chronic Hepatitis B Market, Market Overview
Figure: Global Chronic Hepatitis B Market, Epidemiological Analysis, U.S.
Figure:  Global Chronic Hepatitis B Market, Epidemiological Analysis, EU5
Figure: Global Chronic Hepatitis B Market, Epidemiological Analysis, Rest-of-the-World
Figure: Global Chronic Hepatitis B Market Coverage
Figure: Global Chronic Hepatitis B Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Chronic Hepatitis B Market, Competitive Landscape, January 2022-April 2025